843
Participants
Start Date
October 28, 2020
Primary Completion Date
October 3, 2022
Study Completion Date
October 3, 2022
IIBR-100, low dose (prime)
Single administration of IIBR-100 1\*10E5 pfu/ml
IIBR-100 medium dose (prime)
Single administration of IIBR-100 1\*10E6 pfu/ml
IIBR-100 high-dose (prime)
Single administration of IIBR-100 1\*10E7 pfu/ml
IIBR-100 low-dose (prime-boost)
Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
Saline Placebo (single)
Single administration of saline placebo
Saline Placebo (double)
Two administrations of saline placebo, 28 days apart
IIBR-100 medium-dose (prime-boost)
Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
IIBR-100 high-dose (prime-boost)
Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
IIBR-100 top-dose (prime-boost)
Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan
Hadassah Medical Center, Jerusalem
Assuta - University Hospital, Ashdod
Barzilai MC, Ashkelon
Rambam MC, Haifa
Meir MC, Kfar Saba
Rabin MC, Petah Tikva
Sourasky MC, Tel Aviv
Lead Sponsor
Israel Institute for Biological Research (IIBR)
OTHER_GOV